Metabolite Identification and Profiling
Assessing a drug candidate’s metabolic profile early in the discovery process offers insight into its metabolic clearance pathways in both pre-clinical species and humans. IQVIA Laboratories global bioanalytical and ADME laboratory network offers a range of liquid chromatography/ mass spectrometry services to support discovery and development metabolite identification and profiling.
Specific capabilities using high-resolution mass spectrometry (HRMS) include:
- Metabolite profiling and identification using liver microsomes or hepatocytes, as well as novel hepatocyte co-culture models for profiling slowly metabolized drug candidates
 - Exploratory profiling using unlabeled drug in preclinical and human clinical samples
 - Radio-profiling of both preclinical and human clinical samples
 - Reactive intermediate screens evaluating glutathione/cyanide trapping drug candidates (microsomes)
 
ADME Assays & Metabolite Profiling
To explore how IQVIA Laboratories can partner to characterize metabolites in your study:
A full range of bioanalytical services, including metabolic stability, enzyme identification, metabolite identification, metabolite absorption, metabolite stability assays, and drug-drug interaction assessments - ranging from highly automated screens to definitive studies that enable regulatory submission.
      Related Services
  
  
  ADME / DMPK Services
Learn more
  
  
  Early Hit-to-Lead ADME Screening Bundle
Learn more
  
  
  In Vitro Screening
Learn more
  
  
  Discovery Bioanalysis
Learn more
  
  
  High-Throughput ADME Services
Learn more
  
  
  In Vitro Metabolism
Learn more
  
  
  Assessing your Drug-Drug Interaction Testing Risk
Learn more
  
  
  ADME Assays & Metabolite Profiling and Identification Services
Learn more
  
  
  Metabolite Identification and Profiling
Learn more
  
  
  Bioanalytical Services
Learn more
  
  
  
  
  
  
      
      
      
      
      
      
      
      
      
      
      
      
      
    
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
